Manufacturing: Page 44
-
BMS completes $280 million biologics plant expansion in MA
Previously dedicated only to bulk biologics manufacturing, the site will now be able to support clinical trials of investigational drugs.
By Nicole Gray • May 19, 2016 -
Amid losses, Endo plans cutbacks at Par manufacturing facilities
All told, the restructuring is expected to impact about 740 jobs.
By Ned Pagliarulo • May 12, 2016 -
Sponsored by CRB
Leveraging design to minimize risk
Biotech manufacturers must find ways to minimize their risk by deferring their investment in additional capacity until absolutely necessary.
By Matt Kennedy - Associate, Bioprocess Specialist & Matt Khair - Associate, Core Team Leader, CRB • May 10, 2016 -
Biogen spinoff set to build out hemophilia pipeline
But the decision to separate the hemophilia business has left some analysts bemused over Biogen's true rationale.
By Ned Pagliarulo • May 5, 2016 -
How Aprecia Pharma hopes to tackle patient noncompliance with 3-D printed drug
Aprecia's seizure medication Spritam is the first 3-D printed drug to win FDA approval.
By Nicole Gray • May 3, 2016 -
Alexion eyes new manufacturing investment in Ireland
A number of other large pharma companies have recently expanded their manufacturing presence in the country.
By Nicole Gray • April 28, 2016 -
As new drugs take hold, Lilly ramps up R&D spend
Lilly spent nearly a quarter of its revenue on R&D in 2015 - the third highest figure in the industry.
By Ned Pagliarulo • April 28, 2016 -
Novartis aims for $1 billion in savings from centralization plans
Simultaneously, the company has consolidated the number of third-party suppliers from 100 to 3.
By Nicole Gray • April 28, 2016 -
Chinese FDA to expedite review of new hepatitis C meds
Regulatory review times in China are slow, and approval to start new trials can take over a year.
By Nicole Gray • April 25, 2016 -
Continuing scrutiny, FDA hits Sri Krishna with warning over 'serious' data violations
Inspections of the Indian drugmaker found original records discarded outside the facility.
By Ned Pagliarulo • April 21, 2016 -
China investigates 3 drugmakers for manufacturing violations, orders recall
The investigations come as China continues to deal with a nationwide scandal over the sale of illegal vaccines.
By Ned Pagliarulo • April 21, 2016 -
Sanofi to invest €300 million in Belgian biologics site
In announcing the production expansion, Sanofi also looked toward future launches of several biologics in the coming years.
By Nicole Gray • April 21, 2016 -
Swiss company Lonza Group seeking to acquire CRO Catalent: report
Lonza Group has been expanding in the U.S. recently, acquiring Arch Chemicals in 2011.
By Ned Pagliarulo • April 14, 2016 -
Two Indian generic companies bow to pressure, end appeal for compulsory licenses
BDR Pharma and Lee Pharma were seeking licenses for drugs made by Bristol-Myers Squibb and AstraZeneca.
By Nicole Gray • April 14, 2016 -
FDA advocates for adoption of speedier drug manufacturing technique
One estimate from the White House sees potential for a 40%-50% reduction in manufacturing costs.
By Ned Pagliarulo • April 14, 2016 -
In first, FDA approves Janssen's switch to continuous manufacturing for HIV drug
Vertex, another early adopter of continuous manufacturing, has been using the technique to make Orkambi since the drug's approval in July 2015.
By Nicole Gray • April 14, 2016 -
Sponsored by CRB
The Future of Dosing Technologies: Multiply your Biotech Capacity and Reduce Cost
Microneedle technology is growing in its application and will prove to be one of those disruptive technologies that we will tell our grandchildren about.
By Christa Myers, Sr. Pharmaceutical Engineering Specialist - CRB • April 12, 2016 -
Major NGO drops India's IPCA Labs as a source of anti-malarials
The FDA previously flagged manufacturing violations at three of IPCA's Indian facilities.
By Nicole Gray • April 8, 2016 -
Inspections by FDA hurting Indian drug exports, says Dr. Reddy's chairman
The FDA has stepped up oversight of Indian pharmaceutical manufacturing in the past year over quality concerns.
By Ned Pagliarulo • April 7, 2016 -
Deep Dive
Why partnerships are crucial for pushing vaccine R&D forward
As development costs increase, more collaborations between pharma companies, NGOs, and governments will be needed, according to Dr. Jim Tartaglia, global VP of new vaccines projects at Sanofi Pasteur.
By Ned Pagliarulo • April 7, 2016 -
Lilly invests $40 million in Irish continuous manufacturing facility
Despite several notable advantages, the pharma industry has been slow to shift from batch processing to continuous manufacturing.
By Nicole Gray • April 7, 2016 -
Urging more robust FDA response, lawmakers warn of contaminated heparin
Tainted Chinese supplies of the drug were linked to hundreds of deaths in 2007 and 2008.
By Nicole Gray • March 31, 2016 -
As aging blockbusters come off patent, new opportunities emerge for biosim manufacturers
IMS estimates there are nearly 50 biosimilar drugs in development, which could deliver savings of up to $110 billion in the EU and US over the next five years.
By Ned Pagliarulo • March 31, 2016 -
In quest to expand diabetes market share, Novo breaks ground on $1.8b U.S. plant
The North Carolina facility will produce Novo's insulin and next-gen diabetes medicines when it is completed in 2020.
By Ned Pagliarulo • March 31, 2016 -
Indian drug regulator to begin surprise inspections at manufacturing sites
The Indian government recently banned nearly 350 drugs for safety risks, although many companies have received a stay on the restriction.
By Ned Pagliarulo • March 30, 2016
Previous
